Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Ca

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance is a phase 2, interventional study registered as NCT07509424 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 29 participants, started 2026-04-22 and due to reach its primary completion in 2029-04-10. Interventions recorded: disitamab vedotin, sintilimab, capecitabine. Conditions listed: Rectal Cancer. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: "Subjects are diagnosed with locally advanced rectal cancer by histology and/or cytology, with the lower edge of the tumor ≤10 cm from the anal verge". No results are recorded here; the registry entry is the source.